From my vantage point which is that of a non-scien

Quote:

---

From my vantage point which is that of a non-science trained individual your comment here raises some questions for me. I instinctively think a count of a patient's circulating tumor cells would be a definitive analysis of that patient's prognosis and condition. Yet, it appears, from your comment that the FDA does not share that belief. Is the notion of a high ctc count a new or proven or unproven scientific notion?

---

I'm sure the FDA doesn't look at CTCs as definitive proof of direct effect even with metastasis. They'll want to know if tumors shrank or were eliminated and a comparison of metastatic lesions to best standard of care. It would just prove one of the mechanisms of action for leronlimab.